| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Meds from Amgen, GSK now offered through TrumpRx DTC platform | ||
| Mo | BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts | ||
| Mo | Idorsia shares sink after CEO's abrupt departure | ||
| Mo | Lilly eczema results set up potential expansion of Ebglyss to younger children | ||
| Mo | J&J files trade secret lawsuit against former oncology employee linked to Summit Therapeutics | ||
| Mo | Bayer heads to regulators with nondiabetic kidney disease trial win for Kerendia | ||
| 13.03. | GSK catches up to Pfizer, Moderna with FDA expansion for Arexvy | ||
| 13.03. | Bayer found to have discredited pharma industry after Roche row | ||
| 13.03. | Pfizer CEO Albert Bourla collects $27.6M in 2025 pay following Metsera, MFN deals | ||
| 13.03. | FDA scolds CDMO Simtra with warning letter over contamination fumbles | ||
| 13.03. | 'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success | ||
| 13.03. | FDA fires off another manufacturing-related CRL, this one to Hyloris | ||
| 12.03. | Legend remains bullish on Carvykti growth despite threat from J&J's Tecvayli | ||
| 12.03. | After China outlay, Lilly plugs $126M into Japan manufacturing plant expansion | ||
| 12.03. | Eisai chooses 'Pokémon Sleep' app to battle bad sleep habits in awareness campaign | ||
| 12.03. | FDA rolls out new streamlined adverse event monitoring system, eyes $120M in savings | ||
| 12.03. | In latest compounding clash, Lilly flags high levels of 'impurity' in tirzepatide knockoffs with vitamin B12 | ||
| 12.03. | Rare disease drug sales to surge past $400B by 2032 despite FDA volatility: Evaluate report | ||
| 11.03. | As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 | ||
| 11.03. | AstraZeneca recruits Joshua Jackson, Philadelphia Flyers' Gritty to cancer screening push | ||
| 11.03. | Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement | ||
| 11.03. | Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China | ||
| 11.03. | UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi | ||
| 11.03. | J&J's Joaquin Duato joins $30M CEO pay club with 30% compensation boost for 2025 | ||
| 11.03. | Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales |